IMMUNOBIOLOGY OF CUTANEOUS T CELL LYMPHOMA

皮肤 T 细胞淋巴瘤的免疫生物学

基本信息

  • 批准号:
    3184929
  • 负责人:
  • 金额:
    $ 21.68万
  • 依托单位:
  • 依托单位国家:
    美国
  • 项目类别:
  • 财政年份:
    1986
  • 资助国家:
    美国
  • 起止时间:
    1986-01-01 至 1988-12-31
  • 项目状态:
    已结题

项目摘要

Cutaneous T-cell lymphoma (CTCL) is a malignancy of T lymphocytes, which have the functional and phenotypic properties of helper T cells. This neoplasm has an incidence approximating, and probably exceeding, that of Hodgkin's disease and regularly presents with skin lesions. The natural course of the disease involves evolution of subclones composed of more poorly differentiated T cells that have a decreased affinity for epidermis and an increased propensity to disseminate widely, leading to a median survival of less than 5 years from the time of histopathological diagnosis. These studies have two broad interrelated objectives. First, two monoclonal antibodies (BE1 and BE2), which have specificity for tumor-associated antigens of CTCL cells, will be studied in order to determine their efficacy as diagnostic and potentially therapeutic reagents. The CTCL antigens with which these and other monoclonal antibodies react will be functionally and chemically characterized to determine their relationship to other known membrane markers, as well as to human T lymphoma virus that is a suspected etiological agent for this disease. Second, the possibility that the environment of the epidermis provides a privileged site for the clonal expansion of malignant and benign helper T cells will be explored. In this context, the relationship between, and chemical properties of, two factors produced by epidermal cells (interleukin-1-like and thymopoietin-like factors) will be investigated. It is anticipated that these studies will facilitate better understanding, more efficient diagnosis, and improved therapy of CTCL and that they will also significantly contribute to our knowledge of basic human T-cell biology. (MI)
皮肤T细胞淋巴瘤(CTCL)是一种T淋巴细胞恶性肿瘤

项目成果

期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

RICHARD Leslie EDELSON其他文献

RICHARD Leslie EDELSON的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('RICHARD Leslie EDELSON', 18)}}的其他基金

Protocol Specific Research Support
协议特定研究支持
  • 批准号:
    7513335
  • 财政年份:
    2007
  • 资助金额:
    $ 21.68万
  • 项目类别:
Administration
行政
  • 批准号:
    7513172
  • 财政年份:
    2007
  • 资助金额:
    $ 21.68万
  • 项目类别:
Senior Leadership
高层领导
  • 批准号:
    7513167
  • 财政年份:
    2007
  • 资助金额:
    $ 21.68万
  • 项目类别:
BASIC AND CLINICAL BIOLOGY OF CUTANEOUS T CELL LYMPHOMA
皮肤 T 细胞淋巴瘤的基础和临床生物学
  • 批准号:
    6031934
  • 财政年份:
    2000
  • 资助金额:
    $ 21.68万
  • 项目类别:
YALE COMPREHENSIVE CANCER CENTER
耶鲁大学综合癌症中心
  • 批准号:
    7482247
  • 财政年份:
    1997
  • 资助金额:
    $ 21.68万
  • 项目类别:
YALE COMPREHENSIVE CANCER CENTER
耶鲁大学综合癌症中心
  • 批准号:
    7242083
  • 财政年份:
    1997
  • 资助金额:
    $ 21.68万
  • 项目类别:
CONFERENCE: ANTIGEN AND CLONE-SPECIFIC IMMUNOREGULATION
会议:抗原和克隆特异性免疫调节
  • 批准号:
    3433582
  • 财政年份:
    1990
  • 资助金额:
    $ 21.68万
  • 项目类别:
IMMUNOBIOLOGY OF CUTANEOUS T CELL LYMPHOMA
皮肤 T 细胞淋巴瘤的免疫生物学
  • 批准号:
    2642005
  • 财政年份:
    1986
  • 资助金额:
    $ 21.68万
  • 项目类别:
IMMUNOBIOLOGY OF CUTANEOUS T CELL LYMPHOMA
皮肤 T 细胞淋巴瘤的免疫生物学
  • 批准号:
    3184926
  • 财政年份:
    1986
  • 资助金额:
    $ 21.68万
  • 项目类别:
IMMUNOBIOLOGY OF CUTANEOUS T CELL LYMPHOMA
皮肤 T 细胞淋巴瘤的免疫生物学
  • 批准号:
    3184928
  • 财政年份:
    1986
  • 资助金额:
    $ 21.68万
  • 项目类别:

相似海外基金

Characterization of Naturally Occurring Anti-Blood Group Antibody Formation
天然存在的抗血型抗体形成的表征
  • 批准号:
    9981001
  • 财政年份:
    2017
  • 资助金额:
    $ 21.68万
  • 项目类别:
Characterization of Naturally Occurring Anti-Blood Group Antibody Formation
天然存在的抗血型抗体形成的表征
  • 批准号:
    9751102
  • 财政年份:
    2017
  • 资助金额:
    $ 21.68万
  • 项目类别:
Characterization of Naturally Occurring Anti-Blood Group Antibody Formation
天然存在的抗血型抗体形成的表征
  • 批准号:
    9397073
  • 财政年份:
    2017
  • 资助金额:
    $ 21.68万
  • 项目类别:
Characterization of Naturally Occurring Anti-Blood Group Antibody Formation
天然存在的抗血型抗体形成的表征
  • 批准号:
    10223410
  • 财政年份:
    2017
  • 资助金额:
    $ 21.68万
  • 项目类别:
PREVENTING NEUTRALIZING ANTIBODY FORMATION IN MS PATIENTS WITH SC IFN-BETA (REBI
使用 SC IFN-β (REBI) 预防 MS 患者中和抗体形成
  • 批准号:
    7951676
  • 财政年份:
    2008
  • 资助金额:
    $ 21.68万
  • 项目类别:
PREVENTING NEUTRALIZING ANTIBODY FORMATION IN MS PATIENTS WITH SC IFN-β-AL
预防 SC IFN- 多发性硬化症患者中和抗体的形成
  • 批准号:
    7606036
  • 财政年份:
    2006
  • 资助金额:
    $ 21.68万
  • 项目类别:
IMMUNOLOGIC MECHANISM OF INHIBITOR ANTIBODY FORMATION IN HEMOPHILIA
血友病抑制剂抗体形成的免疫学机制
  • 批准号:
    7375053
  • 财政年份:
    2005
  • 资助金额:
    $ 21.68万
  • 项目类别:
IMMUNOLOGIC MECHANISM OF INHIBITOR ANTIBODY FORMATION IN HEMOPHILIA
血友病抑制剂抗体形成的免疫学机制
  • 批准号:
    7201220
  • 财政年份:
    2004
  • 资助金额:
    $ 21.68万
  • 项目类别:
Immunologic Mechanism of Inhibitor Antibody Formation in Hemophilia
血友病抑制剂抗体形成的免疫学机制
  • 批准号:
    6980810
  • 财政年份:
    2003
  • 资助金额:
    $ 21.68万
  • 项目类别:
INHIBITOR ANTIBODY FORMATION IN HEMOPHILIA AND VON WILLEBRAND'S DISEASE
血友病和冯·维勒布兰德病中的抑制剂抗体形成
  • 批准号:
    6419444
  • 财政年份:
    2000
  • 资助金额:
    $ 21.68万
  • 项目类别:
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了